Compare Entegris Inc (ENTG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs GeneDx Holdings Corp — how do they compare? Entegris Inc trades at $160 (market cap $22.95B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: Entegris Inc is far larger — about 9.4× GeneDx Holdings Corp's market cap, and Entegris Inc pays a 0.27% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ENTG | WGS | |
|---|---|---|
Market Cap | $22.95B | $2.44B |
Sector | Technology | Technology |
52-Week High | $184.00 | $167.51 |
52-Week Low | $68.80 | $34.51 |
Enterprise Value | $26.16B | $2.48B |
Dividend Yield | 0.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG is trading at $161.18, up 11.77% with strong momentum following three consecutive quarterly earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI suggests mild overbought conditions. Recent Q2 2026 results exceeded expectations with 11% revenue growth and 42% EPS growth driven by AI-related semiconductor demand. Analyst consensus remains strongly positive with 66.7% buy ratings and a $188.67 price target representing 17% upside potential.
The outlook remains favorable given ENTG's positioning in advanced semiconductor materials, with AI-driven demand providing tailwinds. However, elevated valuation multiples (P/E 75.11) and execution risks in capacity expansion warrant monitoring. The company's improving cash flow generation and strong institutional interest support continued growth, though semiconductor cycle sensitivity presents the primary risk to sustained performance.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
